The neuro-immune axis: Prospect for novel treatments for mental disorders

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 1, 2014, Pages 128-136

  Kraneveld, Aletta D ^a   de Theije, Caroline G M ^a   van Heesch, Floor ^a   Borre, Yuliya ^a   de Kivit, Sander ^a   Olivier, Berend ^a   Korte, Mechiel ^a   Garssen, Johan ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b DANONE NUTRICIA RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADRENALIN; ALPHA INTERFERON; ANTIBODY; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; CORTICOSTEROID; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROTRANSMITTER; NICOTINIC RECEPTOR; NORADRENALIN; SEROTONIN TRANSPORTER; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE; AUTISM; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFERENT NERVE; EOSINOPHIL; FOOD AVERSION; GRANULOCYTE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATORY DISEASE; INNATE IMMUNITY; INTESTINE FLORA; INTRACELLULAR SIGNALING; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MAJOR DEPRESSION; MAST CELL; META ANALYSIS (TOPIC); MICROGLIA; MONONUCLEAR PHAGOCYTE; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; NONHUMAN; NUCLEUS ACCUMBENS; PAIN RECEPTOR; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SOCIAL INTERACTION; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTISTIC DISORDER; BRAIN; CENTRAL NERVOUS SYSTEM; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; HUMANS; MENTAL DISORDERS;

EID: 84890863959     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12154     Document Type: Review

References (129)

1. Blalock JE, Smith EM. Conceptual development of the immune system as a sixth sense. Brain Behav Immun 2007;21:23-33.
2. Engel MA, Becker C, Reeh PW, Neurath MF. Role of sensory neurons in colitis: increasing evidence for a neuroimmune link in the gut. Inflamm Bowel Dis 2011;17:1030-3.
3. Rosa AC, Fantozzi R. The role of histamine in neurogenic inflammation. Br J Pharmacol 2013;170:38-45.
4. Lampron A, Elali A, Rivest S. Innate immunity in the CNS: redefining the relationship between the CNS and its environment. Neuron 2013;78:214-32.
5. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci 2013;7:45.
6. Jensen CJ, Massie A, De Keyser J. Immune Players in the CNS: the Astrocyte. J Neuroimmune Pharmacol 2013;8:824-39.
7. Ohtori S, Takahashi K, Moriya H, Myers RR. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine (Phila Pa 1976) 2004;29:1082-8.
8. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 2008;173:1768-82.
9. Zhang N, Oppenheim JJ. Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukoc Biol 2005;78:1210-4.
10. Rijnierse A, Kroese AB, Redegeld FA, Blokhuis BR, van der Heijden MW, Koster AS et al. Immunoglobulin-free light chains mediate antigen-specific responses of murine dorsal root ganglion neurons. J Neuroimmunol 2009;208:80-6.
11. Niu N, Zhang J, Guo Y, Zhao Y, Korteweg C, Gu J. Expression and distribution of immunoglobulin G and its receptors in the human nervous system. Int J Biochem Cell Biol 2011;43:556-63.
12. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009;60:355-66.
13. Reardon C, Duncan GS, Brüstle A, Brenner D, Tusche MW, Olofsson PS et al. Lymphocyte-derived ACh regulates local innate but not adaptive immunity. Proc Natl Acad Sci USA 2013;110:1410-5.
14. Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011;334:98-101.
15. Lambrecht BN. Immunologists getting nervous: neuropeptides, dendritic cells and T cell activation. Respir Res 2001;2:133-8.
16. Ganea D, Delgado M. Inhibitory neuropeptide receptors on macrophages. Microbes Infect 2001;3:141-7.
17. Busch-Dienstfertig M, Labuz D, Wolfram T, Vogel NN, Stein C. JAK-STAT1/3-induced expression of signal sequence-encoding proopiomelanocortin mRNA in lymphocytes reduces inflammatory pain in rats. Mol Pain 2012;8:83-95.
18. Busch-Dienstfertig M, Stein C. Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain-basic and therapeutic aspects. Brain Behav Immun 2010;24:683-94.
19. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun 2000;15:331-45.
20. Filippini P, Cesario A, Fini M, Locatelli F, Rutella S. The Yin and Yang of non-neuronal α7-nicotinic receptors in inflammation and autoimmunity. Curr Drug Targets 2012;13:644-55.
21. Nijhuis LE, Olivier BJ, de Jonge WJ. Neurogenic regulation of dendritic cells in the intestine. Biochem Pharmacol 2010;80:2002-8.
22. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002;25:154-9.
23. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
24. McCusker RH, Kelley KW. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol 2013;216:84-98.
25. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol 2013;8:900-20.
26. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012;26:383-92.
27. Altamura AC, Pozzoli S, Fiorentini A. Dell'osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:63-70.
28. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013;246C:199-229.
29. de Theije CG, Wu J, da Silva SL, Kamphuis PJ, Garssen J, Korte SM et al. Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management. Eur J Pharmacol 2011;668:S70-80.
30. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci 2012;1261:55-63.
31. Wiegant DA, Kraneveld AD, Blalock JE. Neuroimmunoendocrinology. Nijkamp FP, Parnham MJ (eds). Principles of Immunopharmacology, 3rd edn. Springer Basel AG, Basel, Switzerland, 2011.
32. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-62.
33. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-86.
34. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57.
35. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004;2004:205-13.
36. Heinze S, Egberts F, Rotzer S, Volkenandt M, Tilgen W, Linse R et al. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial. J Immunother 2010;33:106-14.
37. Hayley S, Scharf J, Anisman H. Central administration of murine interferon-α induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments. Brain Behav Immun 2013;31:115-27.
38. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH. Heim CM Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163:1630-3.
39. Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 2011;16:516-32.
40. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav Immun 2013;31:31-47.
41. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the braimpact on neurotransmitters and neurocircuits. Depress Anxiety 2013;30:297-306.
42. Albert PR, Benkelfat C, Descarries L. The neurobiology of depression-revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci 2012;2012:2378-81.
43. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36:2452-9.
44. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006;6:1298-304.
45. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396-402.
46. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998;33:251-4.
47. Tsao CW, Lin YS, Cheng JT, Lin CF, Wu HT, Wu SR et al. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 2008;22:753-60.
48. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31:2121-31.
49. Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010;35:2510-20.
50. Borowski T, Kokkinidis L, Merali Z, Anisman H. Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. NeuroReport 1998;9:3797-802.
51. Prins J, van Heesch F, de Haan L, Krajnc AM, Kenny PJ, Olivier B et al. Lipolysaccharide-induced changes in brain stimulation reward: anhedonia or sickness behaviour? Eur Neuropsychopharmacol 2011;21:S39-40.
52. van Heesch F, Prins J, Konsman JP, Westphal KG, Olivier B, Kraneveld AD et al. Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study. Brain Behav Immun 2013;29:98-103.
53. Van Heesch F, Prins J, Westphal KGC, Korte-Bouws GAH, Olivier B, Kraneveld AD et al. Pro-inflammatory cytokines induce anhedonia in mice and increase monoamine transporter activity in the nucleus accumbens. Eur Neuropsychopharmacol 2013;23:S47-8.
54. Prins J, Kenny PJ, Doomernik I, Schreiber R, Olivier B, Korte SM. The triple reuptake inhibitor DOV 216, 303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats. Eur J Pharmacol 2012;693:51-6.
55. Bayramgürler D, Karson A, Ozer C, Utkan T. Effects of long-term etanercept treatment on anxiety- and depression-like neurobehaviors in rats. Physiol Behav 2013;119C:145-8.
56. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31-41.
57. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008;13:717-28.
58. Milaneschi Y, Corsi AM, Penninx BW, Bandinelli S, Guralnik JM, Ferrucci L. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry 2009;65:973-8.
59. Maes M, Song C, Yirmiya R. Targeting IL-1 in depression. Expert Opin Ther Targets 2012;16:1097-112.
60. Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E. Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett 2011;32:540-4.
61. Townes SA, Furst DE, Thenkondar A. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation. Open Access Rheumatol: Res Rev 2012;4:87-92.
62. An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab). www.ClinicalTrail.gov NCT01667458.
63. Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002;22:782-90.
64. de Paiva VN, Lima SN, Fernandes MM, Soncini R, Andrade CA. Giusti-Paiva A (2010) Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice. Behav Brain Res 2010;215:146-51.
65. Teeling JL, Cunningham C, Newman TA, Perry VH. The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1. Brain Behav Immun 2010;24:409-19.
66. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot openlabel study. Int Clin Psychopharmacol 2006;21:227-31.
67. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-4.
68. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 2010;178:112-5.
69. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007;68:1056-61.
70. American-Psychiatric-Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, DSM-IV). American Psychiatric Press, Washington, DC, 2000.
71. Morgan JT, Chana G, Pardo GA, Achim C, Semendeferi K, Buckwalter J et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010;68:368-76.
72. Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ et al. Microglia in the cerebral cortex in autism. J Autism Dev Disord 2012;42:2569-84.
73. Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 2005;4:206-10.
74. Ratnayake U, Quinn TA, Castillo-Melendez C, Dickinson H, Walker DW. Behaviour and hippocampus-specific changes in spiny mouse neonates after treatment of the mother with the viral-mimetic Poly I:C at mid-pregnancy. Brain Behav Immun 2012;26:1288-99.
75. Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, Guyenet PG et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012;484:105-9.
76. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57:67-81.
77. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009;207:111-6.
78. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 2006;172:198-205.
79. Jyonouchi H, Geng L, Ruby A, Reddy C, Zimmerman-Bier B. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr 2005;146:605-10.
80. Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 2009;23:124-33.
81. Vojdani A, Mumper E, Granpeesheh D, Mielke L, Traver D, Bock K et al. Low natural killer cell cytotoxic activity in autism: The role of glutathione, IL-2 and IL-15. J Immunol 2008;205:148-54.
82. Heuer L, Ashwood P, Schauer J, Goines P, Krakowiak P, Hertz-Picciotto I et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 2008;1:275-83.
83. Lucarelli S, Frediani T, Zingoni AM, Ferruzzi F, Giardini O, Quintieri F et al. Food allergy and infantile autism. Panminerva Med 1995;37:137-41.
84. Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E et al. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 2002;32:1457-63.
85. Manzardo AM, Henkhaus R, Dhillon S, Butler MG. Plasma cytokine levels in children with autistic disorder and unrelated siblings. Int J Dev Neurosci 2012;30:121-7.
86. Singh VK. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 1996;66:143-5.
87. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011;25:40-5.
88. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 2011;232:196-9.
89. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011;12:453-66.
90. Costa M, Brookes SJ, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut 2000;47:15-9.
91. Peeters B, Noens I, Philips EM, Kuppens S, Benninga MA. Autism Spectrum Disorders in Children with Functional Defecation Disorders. J Pediatr 2013;163:873-8.
92. Louis P. Does the human gut microbiota contribute to the etiology of autism spectrum disorders? Dig Dis Sci 2012;57:1987-9.
93. Schreck KA, Williams K. Food preferences and factors influencing food selectivity for children with autism spectrum disorders. Res Dev Disabil 2006;27:353-63.
94. Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res 2012;5:101-8.
95. Mazurek MO, Vasa RA, Kalb LG, Kanne SM, Rosenberg D, Keefer A et al. Anxiety, sensory over-responsivity, and gastrointestinal problems in children with Autism spectrum disorders. J Abnorm Child Psychol 2012;41:165-76.
96. de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010;51:418-24.
97. Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatr 2011;32:351-60.
98. Costa-Pinto FA, Basso AS. Neural and behavioral correlates of food allergy. Chem Immonol Allergy 2012;98:222-39.
99. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012;13:701-12.
100. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism-comparisons to typical children and correlation with autism severity. BMC Gastroenterol 2011;11:22-35.
101. Theoharides TC. Is a subtype of autism an allergy of the brain? Clin Ther 2013;35:584-91.
102. Jyonouchi H. Food allergy and autism spectrum disorders: is there a link? Curr Allergy Asthma Rep 2009;9:194-201.
103. Meldrum SJ, D'Vaz N, Dunstan JA, Mori TA, Hird K, Simmer K et al. Allergic disease in the first year of life is associated with differences in subsequent neurodevelopment and behaviour. Early Hum Dev 2012;88:567-73.
104. Afzal N, Murch S, Thirrupathy K, Berger L, Fagbemi A, Heuschkel R. Constipation with acquired megarectum in children with autism. Pediatrics 2003;112:939-42.
105. Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008;2: CD003498.
106. Whiteley P, Haracopos D, Knivsberg AM, Reichelt KL, Parlar S, Jacobsen J et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci 2010;13:87-100.
107. Reichelt KL, Knivsberg AM. The possibility and probability of a gut-to-brain connection in autism. Ann Clin Psychiatry 2009;21:205-11.
108. Iebba V, Aloi M, Civitelli F, Cucchiara S. Gut microbiota and pediatric disease. Dig Dis 2011;29:531-9.
109. Basso AS, Pinto FA, Russo M, Britto LR, de Sá-Rocha LC, Palermo Neto J. Neural correlates of IgE-mediated food allergy. J Neuroimmunol 2003;140:69-77.
110. Sutherland MA, Shome GP, Hulbert LE, Krebs N, Wachtel M, McGlone JJ. Acute stress affects the physiology and behavior of allergic mice. Physiol Behav 2009;98:281-7.
111. De Theije CMA, Hofman G, Korkeaviita J, Veening J, Dederen J, Korte SM et al. Neuropsychological changes in a Mouse model for cow's milk allergy. J Neuroimmunol 2012;253:57-8.
112. de Kivit S, Morgan ME, Panagaki T, Kraneveld AD, Garssen J, Oosting R et al. Allergy-induced cognitive abnormalities and neuroinflammation in an OVA-induced food allergy model are prevented by a dietary intervention. J Neuroimmunol 2012;253:89.
113. Mulle JG, Sharp WG, Cubells JF. The gut microbiome: a new frontier in autism research. Curr Psychiatry Rep 2013;15:337-40.
114. Critchfield JW, van Hemert S, Ash M, Mulder L, Ashwood P. The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011;2011:161358.
115. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB et al. Reduced incidence of prevotella and other fermenters in intestinal microflora of autistic children. PLoS ONE 2013;8:e68322.
116. Azas-Braesco V, Bresson JL, Guarner F, Corthier G. Not all lactic acid bacteria are probiotics, but some are. British J Nutr 2010;103:1079-81.
117. de Kivit S, Kraneveld AD, Garssen J, Willemsen LE. Glycan recognition at the interface of the intestinal immune system: target for immune modulation via dietary components. Eur J Pharmacol 2011;668:S124-32.
118. Schouten B, van Esch BC, Hofman GA, van Doorn SA, Knol J, Nauta AJ et al. Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. J Nutr 2009;139:1398-403.
119. van der Aa LB, Heymans HS, van Aalderen WM, Sillevis Smitt JH, Knol J, Ben Amor K et al. Synbad Study Group: Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. Clin Exp Allergy 2010;40:795-804.
120. de Kivit S, Saeland E, Kraneveld AD, van de Kant HJ, Schouten B, van Esch BC et al. Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. Allergy 2012;6:343-52.
121. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002;1572:232-54.
122. de Kivit S, Kraneveld AD, Knippels LM, van Kooyk Y, Garssen J, Willemsen LE. Intestinal epithelium-derived galectin-9 is involved in the immunomodulating effects of nondigestible oligosaccharides. J Innate Immun 2013;5:625-38.
123. Lerman BJ, Hoffman EP, Sutherland ML, Bouri K, Hsu DK, Liu FT et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav 2012;2:563-75.
124. Sävman K, Heyes MP, Svedin P, Karlsson A. Microglia/Macrophage-derived inflammatory mediators Galectin-3 and Quinolinic Acid are elevated in cerebrospinal fluid from newborn infants after birth Asphyxia. Transl Stroke Res 2013;4:228-35.
125. Shin T. The pleiotropic effects of galectin-3 in neuroinflammation: A review. Acta Histochem 2013;115:407-11.
126. Velasco S, Díez-Revuelta N, Hernández-Iglesias T, Kaltner H, André S, Gabius HJ et al. Neuronal Galectin-4 is required for axon growth and for the organization of axonal membrane L1 delivery and clustering. J Neurochem 2013;125:49-62.
127. Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 2012;37:249-63.
128. Sakaguchi M, Okano H. Neural stem cells, adult neurogenesis, and galectin-1: from bench to bedside. Dev Neurobiol 2012;72:1059-67.
129. Yoshida H, Imaizumi T, Kumagai M, Kimura K, Satoh C, Hanada N et al. Interleukin-1beta stimulates galectin-9 expression in human astrocytes. NeuroReport 2001;12:3755-8.